Jacobin Pharma announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2024 (the "AACR 2024") from April 5 to 10, 2024. Details for the 2024 AACR abstracts are as follows: JAB-26766: a small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity Poster Presentation: April 9, 2024, 9:00 AM - 12:30 PM (GMT-7) Session: PO.ET09.01 - DNA Reactive Agents. JAB-26766 is a potent, orally bioavailable PARP7 inhibitor with >1800-fold selectivity on PARP7 over PARP2.

JAB-26766 as a single agent shows potent in vivo anti-tumor activities, which can be further enhanced through combination with STING agonist or anti-PD-1 mAb. JAB-30355: A highly potent, orally bioavailable p53 Y220C reactivator Poster Presentation: April 9, 2024, 1:30 PM - 5:00 PM (GMT-7) Session: PO.ET09.09 - Novel Antitumor Agents 4. JAB-30355 is a potent and selective p53 Y220C reactivator. JAB-30355 exhibited dose-dependent anti-tumor activity, inducing tumor stasis or regression in multiple CDX and PDX models of ovarian cancer, pancreatic cancer, gastric cancer, and small cell lung cancer, with overall good tolerability.

A phase I/IIa clinical trial to evaluate the safety and efficacy of JAB-30355 in patients with advanced solid tumor is ongoing in U.S. The 2024 AACR Annual Meeting will be held in San Diego, California, U.S. from April 5th to April 10th, 2024.